NPR1 and gastric cancer: This mechanism reveals the central role of the MSC-NPRA-Mfn2-FAO axis in chemoresistance of gastric cancer and offers a conceptual foundation for the advancement of therapeutic regimens targeting metabolism or NPRA [29].